Named Bioactive Compounds · Compound
Gambogic Acid (Xanthonoid)
Moderate Evidencexanthonoid3 PubMed Studies
Hermetica Superfood Encyclopedia
Gambogic acid is a xanthonoid compound derived from Garcinia hanburyi that demonstrates potent anticancer activity in laboratory studies. This bioactive xanthone induces cancer cell death through multiple pathways including mitochondrial apoptosis, proteasome inhibition, and ferroptosis activation.
Gambogic acid is a caged xanthonoid compound isolated from gamboge, the dried resin of Garcinia hanburyi (family Clusiaceae). It features a complex tricyclic xanthone backbone with formula C38H44O8 and appears as an amorphous orange solid with poor water solubility.
No human clinical trials, randomized controlled trials, or meta-analyses have been conducted with gambogic acid. All available research consists of preclinical in vitro studies using cancer cell lines (SMMC-7721 hepatoma, MDA-MB-435 breast) and limited animal models, with no PMIDs provided for human studies.
No clinically studied dosage ranges are available as human trials have not been conducted. Preclinical studies use various concentrations in cell culture without standardized protocols or established safe dosing for humans. Consult a healthcare provider before starting any new supplement.
Gambogic acid is not a nutritional substance but a prenylated xanthonoid compound (C38H44O8, MW ~628.75 g/mol) isolated primarily from the resin (gamboge) of Garcinia hanburyi and related Garcinia species. It is a bioactive secondary metabolite, not consumed as a food or dietary supplement in conventional nutrition. Key biochemical characteristics: • Primary bioactive identity: Caged xanthonoid with a unique 4-oxa-tricyclo[4.3.1.0³,⁷]dec-8-en-2-one scaffold • Typical isolation yield: ~0.5–2% w/w from crude gamboge resin, depending on species and extraction method • Solubility: Poorly water-soluble (lipophilic, LogP ~5.5–6.0); requires organic solvents (DMSO, ethanol) or nanoformulation for bioavailability • Bioavailability: Extremely low oral bioavailability in preclinical models (~5–10% estimated in rodents), attributed to poor aqueous solubility, rapid hepatic metabolism (CYP450-mediated oxidation and glucuronidation), and significant first-pass effect • Contains no macronutrients (protein, carbohydrates, fat, fiber) and no vitamins or minerals • Associated co-occurring compounds in gamboge resin include: gambogenic acid, isogambogic acid, morellic acid, isomorellic acid, forbesione, and other xanthonoids/prenylated derivatives (collectively ~15–30 compounds) • Key functional groups responsible for bioactivity: α,β-unsaturated carbonyl (Michael acceptor for thiol-reactive covalent binding to target proteins such as Hsp90, thioredoxin reductase, and transferrin receptor 1), hydroxyl groups, and prenyl side chains • Reported IC50 values in various cancer cell lines: typically 0.5–4 µM range, indicating high potency as a cytotoxic agent • Half-life in plasma (rodent models): approximately 30–80 minutes depending on route of administration • Caution: Gambogic acid and gamboge resin are classified as toxic at higher doses; the compound is not approved as a food ingredient or dietary supplement in any major regulatory jurisdiction (FDA, EFSA, TGA). It is under investigation as an experimental pharmaceutical agent, not a nutritional compound.
Gambogic acid binds to heat shock protein Hsp90, disrupting its chaperone function and destabilizing oncogenic client proteins. The compound activates mitochondrial apoptotic pathways by increasing cytochrome c release and caspase-3 activation. Additionally, gambogic acid induces ferroptosis through iron accumulation and lipid peroxidation, while inhibiting proteasome activity to trigger endoplasmic reticulum stress.
Current evidence for gambogic acid is limited to in vitro cell line studies and animal models, with no human clinical trials completed. Laboratory studies have shown IC50 values ranging from 0.5-5 μM against various cancer cell lines including HeLa, A549, and HepG2. Animal studies in tumor-bearing mice demonstrated dose-dependent tumor growth inhibition at 2-4 mg/kg doses. The lack of human safety and efficacy data represents a significant limitation in evaluating this compound's therapeutic potential.
Safety data for gambogic acid in humans is extremely limited due to the absence of clinical trials. Animal studies have reported hepatotoxicity and gastrointestinal toxicity at higher doses, with LD50 values around 20-30 mg/kg in rodents. No drug interaction studies have been conducted, though theoretical interactions may exist with chemotherapy agents and hepatically metabolized drugs. Pregnancy and lactation safety is unknown, and use should be avoided in these populations due to insufficient safety data.
